Expression profiling of PBMC from patients with hepatocellular carcinoma
收藏官方服务：
资源简介：
Expression profiling of PBMC from patients with hepatocellular carcinoma
应用场景：
创建时间：
2013-08-03
相关数据集
Supplementary Material for: Depth and Duration of Response Are Associated With Survival in Patients With Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
Introduction IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of association
DataCite Commons2025-02-27 更新60
Exploration of exhausted CD8 T cell markers to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma
This study sought to identify transcriptomic and protein markers of T cell exhaustion that may predict response to anti-program cell death-1 (anti-PD-1) / anti-PD-L1-based ICI therapy for patients wit
NIAID Data Ecosystem30
Table_3_Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma.xlsx
Tumor mutation burden (TMB) is associated with immune infiltration, while its underlying mechanism in hepatocellular carcinoma (HCC) remains unclear. A long noncoding RNA (lncRNA)-related competitive
NIAID Data Ecosystem20
HCC Immunotherapy
We collected additional tumor tissues from the initial resection of two early-stage HCC patients for Stereo-seq. These patients were later put on immunotherapy with atezolizumab + bevacizumab after th
Figshare2023-09-23 更新40
Data_Sheet_1_Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.XLS
Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that pred
NIAID Data Ecosystem20
